Skip to main content

Table 1 Clinical characteristic of subjects with CVD at inclusion in the Registry according to statin prescribed, and lipid values at diagnosis of dyslipidemia in the Lipid Clinic without lipid-lowering treatment and after lipid-lowering treatment recorded at inclusion in the Registry

From: Comparative efficacy between atorvastatin and rosuvastatin in the prevention of cardiovascular disease recurrence

VariablesAtorvastatin (n = 243)Rosuvastatin (n = 164)P
Gender (Male), % (n)78.2 [190]68.9 [113]0.046
Age at inclusion, years60.9 (11.1)60.6 (9.9)0.743
Body mass index, (Kg/m2)28.9 (4.1)28.6 (4.3)0.595
ASCVD type (CHD/Stroke/PAD), %77.3/14.5/7.079.3/12.2/5.50.460
Age first ASCVD event51.7 (11.4)51.1 (10.5)0.561
Tobacco consumption, % (n)18.9 [45]15.5 [25]0.461
Hypertension, % (n)48.6 [118]56.1 [92]0.164
Diabetes, % (n)30.9 [75]31.7 [52]0.943
Glucose, mg/dL113.6 (33.5)108.4 (32.4)0.130
Age statin onset48.4 (12.3)49.4 (11.2)0.477
Total cholesterol, mg/dl
 Pre-treatment296.8 (102.6)322.1 (111.1)0.020
 Post-treatment172.9 (55.6)182.6 (49.8)0.065
HDL cholesterol, mg/dl
 Pre-treatment45.2 (14.3)46.6 (12.8)0.285
 Post-treatment47.1 (13.8)49.6 (11.6)0.048
Non-HDL cholesterol, mg/dl
 Pre-treatment251.6 (100.8)275.5 (109.9)0.027
 Post-treatment110.6 (39.9)119.0 (49.5)0.072
Triglycerides, mg/dl
 Pre-treatment241.5 (291.3)209.2 (229.4)0.213
 Post-treatment161.5 (175.2)160.2 (153.8)0.938
Statin daily dose, mg/day50.8 (24.7)21.4 (9.6)
Ezetimibe use, % (n)57.9 [140]69.5 [114]0.023
  1. Values are percentage [count], mean (SD), as applicable. ASCVD Denotes arteriosclerotic cardiovascular disease, CHD Coronary heart disease, PAD Peripheral artery disease, HDL High-density lipoprotein